CD8A and myeloid sarcoma: Interestingly, treatment of MS using anti-CD4 did not eliminate IFN-γ-producing primed Th1 cells and provided no clinical benefit [100], whilst broader depletion of both CD4+ and CD8+ T cells using anti-CD52 resulted in reduced disability and risk of relapse [101].